Managing refractory Crohn's disease: challenges and solutions.
Satoshi Tanida1, Keiji Ozeki1, Tsutomu Mizoshita1
1Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Aichi Prefecture, Japan.
Clinical and Experimental Gastroenterology
|April 28, 2015
Summary
For active Crohn's disease (CD), new therapies beyond conventional treatments and TNF-α inhibitors are crucial. Novel biologics and combination strategies offer improved management for patients with refractory disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Crohn's disease (CD) management aims for remission and improved quality of life.
- Conventional therapies (5-ASA, steroids, purine analogs) and TNF-α inhibitors have limitations like nonresponse and loss of response.
- Refractory CD necessitates alternative treatments with distinct mechanisms of action.
Purpose of the Study:
- To review current and emerging therapeutic options for active Crohn's disease.
- To discuss strategies for managing patients with refractory CD.
Main Methods:
- Literature review of established and investigational CD treatments.
- Analysis of therapeutic mechanisms, including cytokine and adhesion molecule blockade.
- Evaluation of combination therapies and apheresis.
Main Results:
- Established treatments include 5-aminosalicylic acid, corticosteroids, azathioprine, and TNF-α inhibitors.
- Advanced therapies include natalizumab, vedolizumab (integrin blockers), and ustekinumab (IL-12/23 inhibitor).
- Combination therapy (TNF-α inhibitors + azathioprine) and granulocyte and monocyte adsorptive apheresis show promise for refractory cases.
Conclusions:
- Current treatments for moderate-to-severe CD are evolving, with biologics offering new hope.
- Addressing primary nonresponse and loss of response to TNF-α inhibitors is critical.
- Future strategies involve targeted therapies and combination approaches for optimal Crohn's disease management.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
986
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
986
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
716
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
716
01:21Inflammatory Bowel Disease V: Surgical Management
881
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
881
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
666
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
666
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.6K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K